Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Marleen Zuurveld"'
Publikováno v:
Research and Practice in Thrombosis and Haemostasis, Vol 6, Iss 5, Pp n/a-n/a (2022)
Abstract Background Both andexanet alfa and four‐factor prothrombin complex concentrate (4F‐PCC) are clinically applied reversal agents for direct factor Xa inhibitors (FXaIs) in emergency situations. Controversy exists whether 4F‐PCC is as eff
Externí odkaz:
https://doaj.org/article/583703f2c07d49769b9fd32973e174b0
Autor:
Roisin Bavalia, Rahat Abdoellakhan, Herm Jan M. Brinkman, Marjolein P. A. Brekelmans, Eva N. Hamulyák, Marleen Zuurveld, Barbara A. Hutten, Peter E. Westerweel, Renske H. Olie, Hugo ten Cate, Marieke Kruip, Saskia Middeldorp, Karina Meijer, Michiel Coppens
Publikováno v:
Research and Practice in Thrombosis and Haemostasis, Vol 4, Iss 4, Pp 569-581 (2020)
Abstract Background In the initial absence of specific reversal agents for factor Xa inhibitors (FXa‐Is), prothrombin complex concentrate (PCC) as a hemostatic agent has been recommended by guidelines. Since 2017, idarucizumab has been registered f
Externí odkaz:
https://doaj.org/article/c345245df8e24ff4a9568e4a78c0f1cb
Autor:
Herm Jan M. Brinkman, Frauke Swieringa, Marleen Zuurveld, Alicia Veninga, Sanne L. N. Brouns, Johan W. M. Heemskerk, Joost C. M. Meijers
Publikováno v:
Research and Practice in Thrombosis and Haemostasis, Vol 6, Iss 3, Pp n/a-n/a (2022)
Abstract Background Prothrombin complex concentrate (PCC) is a human plasma‐derived mixture of partially purified vitamin K‐dependent coagulation factors (VKCF). Current therapeutic indication is treatment and perioperative prophylaxis of bleedin
Externí odkaz:
https://doaj.org/article/686b1ea5e4d14d848f33507bf2dc4b31
Autor:
Herm Jan M. Brinkman, Saskia Middeldorp, Barbara A. Hutten, Marjolein P. A. Brekelmans, Michiel Coppens, Marieke J. H. A. Kruip, Eva N. Hamulyák, Rahat A. Abdoellakhan, Karina Meijer, Peter E. Westerweel, Hugo ten Cate, Renske H. Olie, Marleen Zuurveld, Roisin Bavalia
Publikováno v:
Research and practice in thrombosis and haemostasis, 4(4), 569-581. Wiley
Research and Practice in Thrombosis and Haemostasis, 4(4), 569-581. Wiley-Blackwell Publishing Ltd
Research and Practice in Thrombosis and Haemostasis
Research and Practice in Thrombosis and Haemostasis, Vol 4, Iss 4, Pp 569-581 (2020)
Research and practice in thrombosis and haemostasis, 4(4), 569-581. Wiley-Blackwell Publishing Ltd
Research and Practice in Thrombosis and Haemostasis, 4(4), 569-581. Wiley-Blackwell Publishing Ltd
Research and Practice in Thrombosis and Haemostasis
Research and Practice in Thrombosis and Haemostasis, Vol 4, Iss 4, Pp 569-581 (2020)
Research and practice in thrombosis and haemostasis, 4(4), 569-581. Wiley-Blackwell Publishing Ltd
Background In the initial absence of specific reversal agents for factor Xa inhibitors (FXa-Is), prothrombin complex concentrate (PCC) as a hemostatic agent has been recommended by guidelines. Since 2017, idarucizumab has been registered for dabigatr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::52f0368b4df92c7256a467c04bad2999
https://hdl.handle.net/11370/90876bf2-f7b8-4774-a8b9-77266e16545a
https://hdl.handle.net/11370/90876bf2-f7b8-4774-a8b9-77266e16545a
Autor:
Marleen Zuurveld, Joost C. M. Meijers, Mikko Manninen, Herm Jan M. Brinkman, Riitta Lassila, Tuukka Helin
Publikováno v:
Transfusion. 58:3014-3026
BACKGROUND: Uncontrollable bleeding is the leading cause of death in traumatically injured patients. The extent to which direct factor Xa inhibitors interfere with the applied resuscitation measures is presently unknown. STUDY DESIGN AND METHODS: In
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::20a9fe454a4ac6e2376bc8e4fbfc5a64
https://doi.org/10.1111/trf.14933
https://doi.org/10.1111/trf.14933
Autor:
Tuukka A, Helin, Marleen, Zuurveld, Mikko, Manninen, Joost C M, Meijers, Riitta, Lassila, Herm Jan M, Brinkman
Publikováno v:
Transfusion. 58(12):3014-3026
BACKGROUND: Uncontrollable bleeding is the leading cause of death in traumatically injured patients. The extent to which direct factor Xa inhibitors interfere with the applied resuscitation measures is presently unknown. STUDY DESIGN AND METHODS: In
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::72be26d243bd92b43fd7d5dfd9bd5d99
https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85055281477&origin=inward
https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85055281477&origin=inward
Autor:
Hanna H. Pitkänen, Wil F. Kopatz, Joost C. M. Meijers, M. Pikta, Herm Jan M. Brinkman, Marleen Zuurveld, Laura Tanner, Harri Niinikoski, Riitta Lassila, Mari Kärki, Kirsti Näntö-Salonen
Publikováno v:
Haemophilia, 24(5), e312-e321. Wiley-Blackwell
Introduction: Lysinuric protein intolerance (LPI), a rare autosomal recessive transport disorder of cationic amino acids lysine, arginine and ornithine, affects intestines, lungs, liver and kidneys. LPI patients may display potentially life-threateni
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bbe5b6d6ce86ecb9171db859d12f1ff1
http://hdl.handle.net/10138/308858
http://hdl.handle.net/10138/308858
Hemostatic profile under fluid resuscitation during rivaroxaban anticoagulation: an in vitro survey.
Autor:
Helin, Tuukka A., Zuurveld, Marleen, Manninen, Mikko, Meijers, Joost C. M., Lassila, Riitta, Brinkman, Herm Jan M.
Publikováno v:
Transfusion; Dec2018, Vol. 58 Issue 12, p3014-3026, 13p, 2 Charts, 6 Graphs